busulfan has been researched along with Mucositis, Oral in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated whether adjusting the oral busulfan (BU) dosage on the basis of early pharmacokinetic data to achieve a targeted drug exposure could reduce transplant-related complications in children with advanced hematologic malignancies." | 7.70 | Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. ( Chan, KW; Choroszy, M; Danielson, M; Felix, EA; Madden, T; Petropoulos, D; Przepiorka, D; Sprigg-Saenz, HA; Tran, HT; Worth, LL, 2000) |
| "All patients are alive with no disease recurrence." | 5.40 | Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. ( Gross, TG; Pai, V; Ranalli, M; Soni, S, 2014) |
| "All patients were transplanted between 1992 and 1999, were >or= 18 years of age, received either cyclophosphamide/total-body irradiation (TBI) or busulfan/cyclophosphamide conditioning regimens, and received four doses of methotrexate for graft-versus-host disease prophylaxis post-transplant." | 3.72 | Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. ( Bruemmer, B; Lloid, ME; Potter, JD; Robien, K; Schubert, MM; Ulrich, CM, 2004) |
| "We investigated whether adjusting the oral busulfan (BU) dosage on the basis of early pharmacokinetic data to achieve a targeted drug exposure could reduce transplant-related complications in children with advanced hematologic malignancies." | 3.70 | Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. ( Chan, KW; Choroszy, M; Danielson, M; Felix, EA; Madden, T; Petropoulos, D; Przepiorka, D; Sprigg-Saenz, HA; Tran, HT; Worth, LL, 2000) |
| "Status of oral mucositis was daily assessed from the first day of conditioning to the 15th day post-HSCT." | 2.94 | Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study. ( Jiang, P; Lu, Y; Ma, Q; Teng, S; Wang, H; Wang, J; Wu, D; Zhou, L; Zhu, X, 2020) |
| "Stomatitis was the most frequent toxicity in both trials." | 2.78 | Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. ( Forman, S; Liu, A; Palmer, J; Radany, E; Rosenthal, J; Schultheiss, T; Somlo, G; Stein, A; Wong, JY, 2013) |
| "The incidence of toxicity excluding oral mucositis was low, and there was no regimen-related toxicity-associated mortality." | 2.73 | Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. ( Abe, Y; Choi, I; Eto, T; Hara, S; Nagafuji, K; Ogata, K; Sasaki, N; Suzumiya, J; Takamatsu, Y; Tamura, K, 2007) |
| "the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy." | 2.72 | Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience. ( Horvath, N; Keefe, D; Lees, J, 2006) |
| " A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics." | 2.70 | A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ( Aschan, J; Eber, S; Gungor, T; Hassan, M; Hassan, Z; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O; Seger, R; Winiarski, J, 2002) |
| " We investigated a 6-h and a 34-h infusion of VP-16 to compare pharmacokinetic parameters and toxicity." | 2.67 | Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. ( Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Reifke, J; Stockschläder, M; Zander, A, 1994) |
| "To evaluate the toxic extramedullary morbidity of the conditioning treatment with BuCy for BMT, as well as the usefulness of pentoxyphyllin (PTX) and methylprednisolone (MP) in the prophylaxis of mucositis." | 2.39 | [Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning]. ( Maldonado, J; Pascual, MJ, 1995) |
| "Of the 142 patients analyzed, oral mucositis and diarrhea (representing GI mucositis) were reported as 68." | 1.91 | Prospective longitudinal analysis of clinical and immunological risk factors associated with oral and gastrointestinal mucositis following autologous stem cell transplant in adults. ( Law, KB; Lee, CS; Lim, YAL; Rajasuriar, R; Tan, SM; Wong, SP, 2023) |
| "All patients are alive with no disease recurrence." | 1.40 | Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. ( Gross, TG; Pai, V; Ranalli, M; Soni, S, 2014) |
| "Oral mucositis was reduced in patients treated with RIC and in patients treated during recent years, when oral care was intensified." | 1.40 | Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. ( Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O, 2014) |
| "A reduction in oral mucositis score (P < 0." | 1.40 | Protective effects of aqueous extract of Solanum nigrum Linn. leaves in rat models of oral mucositis. ( Biswas, S; Nandakumar, K; Patel, A; Ramalingayya, GV; Shoja, MH, 2014) |
| " Body surface area-based dosing in the FLU/MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2." | 1.35 | Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. ( Karas, M; Koza, V; Steinerova, K; Vokurka, S, 2009) |
| "To establish a rat model of oral mucositis (OM) induced by busulfan and cyclophosphamide (BUCY) conditioning regimen of hematopoietic stem cell transplantation (HSCT)." | 1.34 | [Establishment of an animal model of oral mucositis induced by conditioning regimen of haematopoietic stem cell transplantation]. ( Chen, XB; Tong, XZ; Wang, X, 2007) |
| "Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality." | 1.31 | Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. ( Benni, M; Cavo, M; Motta, MR; Rizzi, S; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2000) |
| "The pattern of oral mucositis and related treatment variables was studied in 20 bone marrow transplant patients." | 1.28 | Relationships between oral mucositis and treatment variables in bone marrow transplant patients. ( Ortlieb, ML; Parkerson, SG; Spitzer, T; Zerbe, MB, 1992) |
| "Cancrum oris is predominantly seen in children in underdeveloped countries where widespread malnutrition, dehydration and epidemic infections are present." | 1.28 | Cancrum oris-like lesions. ( Cheng, LH; Nash, ES; Smart, K, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Grossman, A | 1 |
| Froggatt, N | 1 |
| Hendricks, L | 1 |
| Kannenberg, M | 1 |
| Klink, K | 1 |
| Koch, N | 1 |
| Reid, K | 1 |
| Pitcher, D | 1 |
| Bullock, P | 1 |
| Neubauer, J | 1 |
| Wong, SP | 1 |
| Tan, SM | 1 |
| Lee, CS | 1 |
| Law, KB | 1 |
| Lim, YAL | 1 |
| Rajasuriar, R | 1 |
| de Paula Eduardo, F | 1 |
| Bezinelli, LM | 1 |
| Carvalho, DLC | 1 |
| Ferreira, MH | 1 |
| Gobbi, M | 1 |
| Rosin, FCP | 1 |
| Dos Santos Ferreira, CE | 1 |
| Sodre da Costa, LS | 1 |
| Hamerschlak, N | 1 |
| Corrêa, L | 1 |
| Torihata, S | 1 |
| Mukai, T | 1 |
| Uchihashi, T | 1 |
| Matsunaga, K | 1 |
| Miki, H | 1 |
| Yasumoto, M | 1 |
| Yasutake, N | 1 |
| Ashida, A | 1 |
| Enomoto, A | 1 |
| Hamada, S | 1 |
| Ashida, T | 1 |
| Jung, SH | 1 |
| Lee, JJ | 1 |
| Kim, JS | 1 |
| Min, CK | 1 |
| Kim, K | 1 |
| Choi, Y | 1 |
| Eom, HS | 1 |
| Joo, YD | 1 |
| Kim, SH | 1 |
| Kwak, JY | 1 |
| Kang, HJ | 1 |
| Lee, JH | 1 |
| Lee, HS | 1 |
| Mun, YC | 1 |
| Moon, JH | 1 |
| Sohn, SK | 1 |
| Park, SK | 1 |
| Park, Y | 1 |
| Shin, HJ | 1 |
| Yoon, SS | 1 |
| Lu, Y | 1 |
| Zhu, X | 1 |
| Ma, Q | 1 |
| Wang, J | 1 |
| Jiang, P | 1 |
| Teng, S | 1 |
| Zhou, L | 1 |
| Wu, D | 2 |
| Wang, H | 1 |
| Soni, S | 1 |
| Pai, V | 1 |
| Gross, TG | 1 |
| Ranalli, M | 1 |
| Legert, KG | 1 |
| Remberger, M | 1 |
| Ringdén, O | 2 |
| Heimdahl, A | 1 |
| Dahllöf, G | 1 |
| Boztug, H | 1 |
| Zecca, M | 1 |
| Sykora, KW | 1 |
| Veys, P | 1 |
| Lankester, A | 1 |
| Slatter, M | 1 |
| Skinner, R | 1 |
| Wachowiak, J | 1 |
| Pötschger, U | 1 |
| Glogova, E | 1 |
| Peters, C | 1 |
| Patel, A | 1 |
| Biswas, S | 1 |
| Shoja, MH | 1 |
| Ramalingayya, GV | 1 |
| Nandakumar, K | 1 |
| Berger, K | 1 |
| Schopohl, D | 1 |
| Rieger, C | 1 |
| Ostermann, H | 1 |
| Chaudhry, HM | 1 |
| Bruce, AJ | 1 |
| Wolf, RC | 1 |
| Litzow, MR | 1 |
| Hogan, WJ | 1 |
| Patnaik, MS | 1 |
| Kremers, WK | 1 |
| Phillips, GL | 1 |
| Hashmi, SK | 1 |
| Vokurka, S | 1 |
| Steinerova, K | 1 |
| Karas, M | 1 |
| Koza, V | 1 |
| Sobecks, RM | 1 |
| Rybicki, L | 1 |
| Yurch, M | 1 |
| Kalaycio, M | 1 |
| Dean, R | 1 |
| Andresen, S | 1 |
| Pohlman, B | 1 |
| Duong, H | 1 |
| Bolwell, B | 1 |
| Copelan, E | 1 |
| Wong, JY | 1 |
| Forman, S | 1 |
| Somlo, G | 1 |
| Rosenthal, J | 1 |
| Liu, A | 1 |
| Schultheiss, T | 1 |
| Radany, E | 1 |
| Palmer, J | 1 |
| Stein, A | 1 |
| Ritchie, DS | 1 |
| Szer, J | 3 |
| Roberts, AW | 1 |
| Shuttleworth, P | 1 |
| Grigg, AP | 2 |
| Hassan, M | 1 |
| Nilsson, C | 1 |
| Hassan, Z | 1 |
| Gungor, T | 1 |
| Aschan, J | 1 |
| Winiarski, J | 1 |
| Hentschke, P | 1 |
| Eber, S | 1 |
| Seger, R | 1 |
| Ljungman, P | 1 |
| CLIFFORD, P | 1 |
| CLIFT, RA | 1 |
| KHAN, AG | 1 |
| TIMMIS, GM | 1 |
| Robien, K | 1 |
| Schubert, MM | 1 |
| Bruemmer, B | 1 |
| Lloid, ME | 1 |
| Potter, JD | 1 |
| Ulrich, CM | 1 |
| Keefe, D | 1 |
| Lees, J | 1 |
| Horvath, N | 1 |
| Takamatsu, Y | 1 |
| Sasaki, N | 1 |
| Eto, T | 1 |
| Nagafuji, K | 1 |
| Abe, Y | 1 |
| Choi, I | 1 |
| Ogata, K | 1 |
| Hara, S | 1 |
| Suzumiya, J | 1 |
| Tamura, K | 1 |
| Chen, XB | 1 |
| Wang, X | 1 |
| Tong, XZ | 1 |
| Rosenthal, MA | 1 |
| Sheridan, WP | 1 |
| Pascual, MJ | 1 |
| Maldonado, J | 1 |
| Mross, K | 1 |
| Bewermeier, P | 1 |
| Reifke, J | 1 |
| Krüger, W | 1 |
| Stockschläder, M | 1 |
| Zander, A | 1 |
| Hossfeld, DK | 1 |
| Srivastava, A | 1 |
| Bradstock, KF | 1 |
| de Bortoli, L | 1 |
| Gottlieb, DJ | 1 |
| Tosi, P | 1 |
| Zamagni, E | 1 |
| Ronconi, S | 1 |
| Benni, M | 1 |
| Motta, MR | 1 |
| Rizzi, S | 1 |
| Tura, S | 1 |
| Cavo, M | 1 |
| Tran, HT | 1 |
| Madden, T | 1 |
| Petropoulos, D | 1 |
| Worth, LL | 1 |
| Felix, EA | 1 |
| Sprigg-Saenz, HA | 1 |
| Choroszy, M | 1 |
| Danielson, M | 1 |
| Przepiorka, D | 1 |
| Chan, KW | 1 |
| Zhu, K | 1 |
| Xu, Y | 1 |
| Xu, X | 1 |
| Huang, L | 1 |
| Lieschke, GJ | 1 |
| Ramenghi, U | 1 |
| O'Connor, MP | 1 |
| Sheridan, W | 1 |
| Morstyn, G | 1 |
| Zerbe, MB | 1 |
| Parkerson, SG | 1 |
| Ortlieb, ML | 1 |
| Spitzer, T | 1 |
| Nash, ES | 1 |
| Cheng, LH | 1 |
| Smart, K | 1 |
| Levantine, A | 1 |
| Almeyda, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study[NCT03203733] | 182 participants (Actual) | Interventional | 2017-06-12 | Completed | |||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637] | Phase 3 | 84 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for busulfan and Mucositis, Oral
| Article | Year |
|---|---|
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2016 |
[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning].
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Arrhythmias, Cardiac; Bone Marrow Tran | 1995 |
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor | 1974 |
9 trials available for busulfan and Mucositis, Oral
| Article | Year |
|---|---|
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
Topics: Administration, Intravenous; Adult; Aged; Busulfan; Female; Humans; Infections; Male; Melphalan; Mid | 2018 |
Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study.
Topics: Adult; Busulfan; Cryotherapy; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transpla | 2020 |
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Ther | 2013 |
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etopo | 2002 |
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Topics: Adult; Age Factors; Busulfan; Child; Cyclophosphamide; Drug Administration Schedule; Drug Carriers; | 2002 |
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cancer Care | 2006 |
Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation.
Topics: Administration, Oral; Adult; Asian People; Busulfan; Female; Graft Survival; Hematologic Neoplasms; | 2007 |
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan | 1994 |
21 other studies available for busulfan and Mucositis, Oral
| Article | Year |
|---|---|
Oral Cryotherapy for Oral Mucositis in Patients Receiving Busulfan: A Retrospective/Prospective Descriptive Study.
Topics: Busulfan; Cryotherapy; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Retrosp | 2022 |
Prospective longitudinal analysis of clinical and immunological risk factors associated with oral and gastrointestinal mucositis following autologous stem cell transplant in adults.
Topics: Adolescent; Adult; Busulfan; Cytokines; Female; Hematopoietic Stem Cell Transplantation; Humans; Imm | 2023 |
Is Salivary Busulfan the Cause of Oral Mucositis and the Changes in Salivary Antioxidant Enzymes After Hematopoietic Cell Transplantation?
Topics: Aged; Antioxidants; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; | 2020 |
Influences of FLU/BU and FLU/MEL on incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; In | 2017 |
Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution.
Topics: Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Infusions, Intravenou | 2014 |
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosp | 2014 |
Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Diarr | 2015 |
Protective effects of aqueous extract of Solanum nigrum Linn. leaves in rat models of oral mucositis.
Topics: Animals; Body Weight; Busulfan; Chromatography, High Pressure Liquid; Disease Models, Animal; Feedin | 2014 |
Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Busulfan; Drug Costs; Female; German | 2015 |
Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Female; Hematopoietic St | 2009 |
Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; | 2012 |
DIMETHYL MYLERAN THERAPY COMBINED WITH ABDOMINAL AORTIC OCCLUSION.
Topics: Adolescent; Alopecia; Aorta; Aorta, Abdominal; Busulfan; Chemotherapy, Cancer, Regional Perfusion; D | 1964 |
Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia.
Topics: Adolescent; Adult; Body Mass Index; Busulfan; Cyclophosphamide; Female; Genotype; Graft vs Host Dise | 2004 |
[Establishment of an animal model of oral mucositis induced by conditioning regimen of haematopoietic stem cell transplantation].
Topics: Animals; Busulfan; Cyclophosphamide; Disease Models, Animal; Feasibility Studies; Hematopoietic Stem | 2007 |
Busulphan and melphalan prior to autologous bone marrow transplantation.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone | 1993 |
Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 2000 |
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2000 |
[The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
Topics: Acute Disease; Adult; Busulfan; Cyclophosphamide; Cystitis; Disease-Free Survival; Esophagitis; Fema | 2000 |
Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Granulocyte Colo | 1992 |
Relationships between oral mucositis and treatment variables in bone marrow transplant patients.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; District of Columbia; Etoposide; Fem | 1992 |
Cancrum oris-like lesions.
Topics: Ampicillin; Busulfan; Candida albicans; Chronic Disease; Diagnosis, Differential; Disease Susceptibi | 1991 |